NEW YORK, Sept. 19, 2016 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Neos Therapeutics, Inc. ("Neos" or the "Company") (NASDAQ: NEOS) (ISIN: JP3832370005). Investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. 9980.
The investigation concerns whether Neos and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On October 19, 2015, Neos Therapeutics disclosed that the U.S. Food and Drug Administration had identified deficiencies in the Company's new drug application for Cotempla XR-ODT that precluded discussion of labeling and marketing requirements at that time. On this news, Neos stock fell more than 23% during intraday trading on October 20, 2015.
On August 11, 2016, Neos announced its financial and operating results for the second quarter of 2016, reporting that the Company had missed its earnings expectations by a significant $0.49 per share. On this news, Neos stock fell $1.30, or 15.17%, to close at $7.27 on August 11, 2016.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com
Robert S. Willoughby
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-neos-therapeutics-inc--neos-300330101.html
SOURCE Pomerantz LLP